--- title: "ERAS 投资者警报：Kirby McInerney LLP 正在调查涉及 Erasca, Inc.的潜在索赔" type: "News" locale: "zh-CN" url: "https://longbridge.com/zh-CN/news/286975698.md" description: "Kirby McInerney LLP 正在调查针对 Erasca, Inc.（纳斯达克代码：ERAS）的潜在索赔，涉及在 Revolution Medicines 提出的专利侵权指控后可能违反联邦证券法的情况。这一消息导致 Erasca 的股票下跌了约 48%。目前尚未提起诉讼，调查仍在进行中。拥有信息或感兴趣的投资者被鼓励与该律师事务所联系" datetime: "2026-05-19T23:12:50.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/286975698.md) - [en](https://longbridge.com/en/news/286975698.md) - [zh-HK](https://longbridge.com/zh-HK/news/286975698.md) --- # ERAS 投资者警报：Kirby McInerney LLP 正在调查涉及 Erasca, Inc.的潜在索赔 **ERAS INVESTOR ALERT: Kirby McInerney LLP Investigates Potential Claims Involving Erasca, Inc.** The law firm of Kirby McInerney LLP continues its investigation on behalf of Erasca, Inc. (“Erasca” or the “Company”) (NASDAQ:ERAS) investors concerning the Company’s and/or members of its senior management’s possible violation of the federal securities laws and other unlawful business practices. \[LEARN MORE ABOUT THE INVESTIGATION\] **What Happened?** On April 28, 2026, Erasca disclosed receipt of a letter from Revolution Medicines alleging that Erasca’s ERAS-0015 (Erasca’s Phase-1 oral pan-RAS molecular glue inhibitor designed to target cancers) infringes a Revolution patent and is connected to alleged trade secret misappropriation. On this news, the price of Erasca’s shares declined by $9.25 per share, or approximately 48%, from $19.15 per share on April 27, 2026 to close at $9.90 on April 28, 2026. **What Should I Do?** At this stage, no lawsuit has been filed. The investigation is ongoing to determine whether claims may be brought under federal securities laws. If you purchased or otherwise acquired Erasca securities, have information, or would like to learn more about this investigation, please contact Lauren Molinaro of Kirby McInerney LLP by email at investigations@kmllp.com, or fill out the contact form below, to discuss your rights or interests with respect to these matters at no cost. \[LEARN MORE ABOUT SECURITIES CLASS ACTIONS\] Kirby McInerney LLP is a New York-based plaintiffs’ law firm concentrating in securities, antitrust, whistleblower, and consumer litigation. The firm’s efforts on behalf of shareholders in securities litigation have resulted in recoveries totaling billions of dollars. Additional information about the firm can be found at Kirby McInerney LLP’s website. This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules. Kirby McInerney LLP Lauren Molinaro, Esq. 212-699-1171 https://www.kmllp.com https://securitiesleadplaintiff.com/ investigations@kmllp.com View source version on businesswire.com: https://www.businesswire.com/news/home/20260519928781/en/ ### 相关股票 - [ERAS.US](https://longbridge.com/zh-CN/quote/ERAS.US.md) - [RVMD.US](https://longbridge.com/zh-CN/quote/RVMD.US.md) - [PBE.US](https://longbridge.com/zh-CN/quote/PBE.US.md) - [SBIO.US](https://longbridge.com/zh-CN/quote/SBIO.US.md) - [XBI.US](https://longbridge.com/zh-CN/quote/XBI.US.md) - [IBB.US](https://longbridge.com/zh-CN/quote/IBB.US.md) - [ARKG.US](https://longbridge.com/zh-CN/quote/ARKG.US.md) - [LABU.US](https://longbridge.com/zh-CN/quote/LABU.US.md) - [BBH.US](https://longbridge.com/zh-CN/quote/BBH.US.md) - [FBT.US](https://longbridge.com/zh-CN/quote/FBT.US.md) - [BIB.US](https://longbridge.com/zh-CN/quote/BIB.US.md) - [RVMDW.US](https://longbridge.com/zh-CN/quote/RVMDW.US.md) ## 相关资讯与研究 - [“搞钱”，才是 Revolution 千亿神话密码](https://longbridge.com/zh-CN/news/286888792.md) - [Erasca 在美国银行会议上展示了令人瞩目的 ERAS-0015 肺癌数据，并讨论了 FDA 审批路径](https://longbridge.com/zh-CN/news/286652404.md) - [CAR-T 迎接新时代](https://longbridge.com/zh-CN/news/286999381.md) - [创胜集团医药-B 合作伙伴 INHIBRX 报告 OZEKIBART 的 CRC 最新积极数据并宣布就治疗软骨肉瘤提交美国 BLA 申请](https://longbridge.com/zh-CN/news/287126678.md) - [Tevogen Bio Q1 运营亏损收窄 48%，推进 AI 平台与细胞疗法管线](https://longbridge.com/zh-CN/news/287086570.md)